<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Exp Hematop</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Exp Hematop</journal-id><journal-id journal-id-type="publisher-id">jslrt</journal-id><journal-title-group><journal-title>Journal of Clinical and Experimental Hematopathology : JCEH</journal-title></journal-title-group><issn pub-type="ppub">1346-4280</issn><issn pub-type="epub">1880-9952</issn><publisher><publisher-name>JSLRT</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31708516</article-id><article-id pub-id-type="pmc">6954166</article-id><article-id pub-id-type="publisher-id">19026</article-id><article-id pub-id-type="doi">10.3960/jslrt.19026</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Potential mechanisms of spontaneous regression in patients with B-cell lymphoma; the significance of co-stimulatory molecules in lymphoma cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Komohara</surname><given-names>Yoshihiro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Harada</surname><given-names>Mamoru</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1)</label>Department of Cell Pathology, Graduate School of Medical Sciences, <institution>Kumamoto University</institution>, <addr-line>Kumamoto</addr-line>, <country>Japan</country>,</aff><aff><target id="aff2" target-type="aff"><sup>2)</sup></target>Department of Immunology, Faculty of Medicine, <institution>Shimane University</institution>, <addr-line>Shimane</addr-line>, <country>Japan</country>, <target id="aff3" target-type="aff"><sup>3)</sup></target>Center for Metabolic Regulation of Healthy Aging, <institution>Kumamoto University</institution>, <addr-line>Kumamoto</addr-line>, <country>Japan</country></aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Yoshihiro Komohara, Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan., E-mail: <email xlink:href="ycomo@kumamoto-u.ac.jp">ycomo@kumamoto-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>59</volume><issue>4</issue><fpage>207</fpage><lpage>210</lpage><history><date date-type="received"><day>24</day><month>7</month><year>2019</year></date><date date-type="rev-recd"><day>25</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>08</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by The Japanese Society for Lymphoreticular Tissue Research</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Japanese Society for Lymphoreticular Tissue
Research</copyright-holder><license specific-use="CC BY-NC-SA 4.0" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License.</license-p></license></permissions><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>spontaneous regression</kwd><kwd>remission</kwd><kwd>lymphoma</kwd></kwd-group></article-meta></front><body><sec sec-type="other1"><title>TO THE EDITOR</title><p>Spontaneous regression (SR) of malignant tumors has been observed in several types of tumors including lymphoma, kidney cancer, melanoma, and neuroblastoma.<xref rid="r1" ref-type="bibr"><sup>1</sup></xref> SR is currently of interest for many clinicians because of an increased number of methotrexate-related lymphoproliferative disorders, and because SR is observed in many patients after withdrawal of methotrexate.<xref rid="r2" ref-type="bibr"><sup>2</sup></xref> In terms of a mechanism, anti-tumor immune responses by host T lymphocytes reacting against tumor cells are believed to be involved in SR,<xref rid="r3" ref-type="bibr"><sup>3</sup></xref> and several cases have recently been reported. In a recent issue of journal of clinical and experimental hematopathology (<italic>JCEH</italic>), Tanaka <italic>et al</italic>. described a case of diffuse large B-cell lymphoma (DLBCL) with SR.<xref rid="r4" ref-type="bibr"><sup>4</sup></xref> A 35-year-old man had multiple mesenteric lymphadenopathy and a thickened small intestine wall, and was diagnosed with DLBCL (germinal center origin) without infection with Epstein-Barr virus (EBV) following laparoscopic lymph node biopsy. However, symptoms were improved and abnormal accumulation of fluorodeoxyglucose was disappeared 3 months after the biopsy. In addition, Abe <italic>et al</italic>. previously reported in <italic>JCEH</italic> a case of DLBCL harboring EBV infection with SR and reviewed some published SR cases of aggressive non-Hodgkin&#x02019;s lymphoma.<xref rid="r5" ref-type="bibr"><sup>5</sup></xref> SR has also been seen in low-grade lymphoma. Matsuo <italic>et al</italic>. described a case of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue with SR.<xref rid="r6" ref-type="bibr"><sup>6</sup></xref> Ye <italic>et al</italic>. just recently published four cases of SR in patients with mantle cell lymphoma.<xref rid="r7" ref-type="bibr"><sup>7</sup></xref> SR is preferentially seen in extranodal lymphoma including in the intestinal tract.</p><p>SR (also referred as &#x0201c;healing&#x0201d;) is also observed in patients with non-hematological malignant tumors such as lung cancer, kidney cancer, breast cancer, and melanoma.<xref rid="r8" ref-type="bibr"><sup>8</sup></xref><sup>-</sup><xref rid="r11" ref-type="bibr"><sup>11</sup></xref> These solid cancers are known as immunogenic tumors because of increased expression of neoantigens, and anti-tumor therapy using immune checkpoint blockade antibodies and cytokines such as interferons have been used for these cancers.<xref rid="r12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="r13" ref-type="bibr"><sup>13</sup></xref> However, mutation burdens of high-grade lymphomas are less than those of melanoma and lung cancers, indicating that unknown mechanisms are involved in SR in lymphoma cases.<xref rid="r14" ref-type="bibr"><sup>14</sup></xref></p><p>CD80 and CD86 are well-known co-stimulatory molecules expressed on antigen-presenting cells including B cells. CD80 is expressed on lymphoma cells in 90% of DLBCL cases,<xref rid="r15" ref-type="bibr"><sup>15</sup></xref> and the expression of both CD80 and CD86 is widely seen in leukemia or lymphoma cell lines in the NCI-60 cancer panel database [GEO data set, GDS4296]. As shown in <xref ref-type="fig" rid="f1">figure 1</xref>, CD80 expression was observed in B-cell lymphoma and B-cell lymphoma cell lines. In addition, human leukocyte antigen (HLA)-DR, one of major histocompatibility complex (MHC) class II molecules, is also expressed in 65% of DLBCL cases, and HLA-DR-positive cases show a significantly better clinical course.<xref rid="r16" ref-type="bibr"><sup>16</sup></xref> Given that lymphoma cells in DLBCL expressing co-stimulatory molecules such as CD80/CD86 and MHC class II molecules, lymphoma cells may have the higher immunogenic potential than other solid tumors. In support of this, Allison (received the Nobel Prize in 2018) <italic>et al</italic>. previously found that ectopic expression of CD80 on tumor cells induces T cell-mediated rejection in murine models by not CD4-positive T cells but CD8-positive T cells.<xref rid="r17" ref-type="bibr"><sup>17</sup></xref> In addition, clinical trials with tumor cell vaccines using CD80-transfected autologous or allogenic tumor cells were performed for kidney cancer, lung cancer, and acute myeloid leukemia.<xref rid="r18" ref-type="bibr"><sup>18</sup></xref> As a result, some patients who enrolled in these trials showed significant tumor reduction.<xref rid="r19" ref-type="bibr"><sup>19</sup></xref><sup>-</sup><xref rid="r21" ref-type="bibr"><sup>21</sup></xref> Although the overall response rate was limited, these findings indicate that CD80-expressing tumor cells could enhance anti-tumor immune responses. The interaction between CD80/CD86 and CD28 activates tumor-specific T cells to produce interleukin (IL)-2, which in turn triggers T cell proliferation in autocrine and paracrine manners in tumor microenvironment (<xref ref-type="fig" rid="f2">Figure 2</xref>). Given that the interaction between CD80/86 and CTLA-4 results in T cell inactivation, therapies to block CTLA-4-mediated immunosuppression may improve this immune response.</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>CD80 expression in lymphoma tissues and cell lines. (<italic>A</italic>) The immunostaining using anti-CD80 monoclonal antibody (clone EPR1157, Abcam) was performed as described previous methods.<xref rid="r30" ref-type="bibr"><sup>30</sup></xref> Lymphoma cells were weakly positive for CD80 in diffuse large B-cell lymphoma (<italic>A</italic>), and strongly positive in two B-cell lymphoma cell lines (SLVL and BALL1) (<italic>B</italic>). Scale bar; 20&#x003bc;m.</p></caption><graphic xlink:href="jslrt-59-207-g001"/></fig><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Scheme of the suggested mechanisms of spontaneous regression (SR). (<italic>A</italic>) In the growing phase of lymphoma, lymphoma cells are protected from microenvironment that includes cytotoxic T lymphocytes. Stress or injury disrupts the microenvironment, and immune reactions between T lymphocytes and lymphoma cells can be initiated. (<italic>B</italic>) Co-stimulatory molecules such as CD80/CD86 stimulate lymphoma-specific T cell response. Activated T lymphocytes proliferate and attack lymphoma cells, which present neoantigens or viral antigens with HLA class I or class II molecules.</p></caption><graphic xlink:href="jslrt-59-207-g002"/></fig><p>Regarding EBV-infected lymphoma or lymphoproliferation, anti-EBV immune responses are believed to induce anti-lymphoma immune responses and SR.<xref rid="r22" ref-type="bibr"><sup>22</sup></xref> However, EBV-transformed B lymphocytes and EBV-infected lymphoma cells produce IL-12, which is a cytokine to promote cellular immunity and is produced after CD40 ligation.<xref rid="r23" ref-type="bibr"><sup>23</sup></xref> IL-12 production from lymphoma cells may be involved in SR in EBV-infected lymphoma or lymphoproliferative disorders.</p><p>Traumatic stress or injury including biopsy is considered to be a trigger for SR, and occasionally, administration of corticosteroids, anti-lymphoma drugs, or infection may cause the initiation of SR.<xref rid="r1" ref-type="bibr"><sup>1</sup></xref><sup>-</sup><xref rid="r3" ref-type="bibr"><sup>3</sup></xref> We propose a possibility that, after lymphoma cells are exposed to anti-lymphoma T lymphocytes by physical disruption of the microenvironment, immune reaction between lymphoma cells and lymphoma-specific T lymphocytes may be initiated. Damage-associated molecular patterns are also considered to be involved in this immune reaction by activating the STING pathway in antigen-presenting cells.<xref rid="r24" ref-type="bibr"><sup>24</sup></xref></p><p>Recent advances of immunotherapy indicated the significance of programmed death-1 (PD-1) and its ligands such as PD-L1 and PD-L2. PD-L1-expression in lymphoma cells was seen in 11% of cases and reportedly associated to poor clinical course in DLBCL.<xref rid="r25" ref-type="bibr"><sup>25</sup></xref> PD-L1 expression in lymphoma cells were potentially mediated by Stat3 activation which were suggested to be induced by macrophage-derived factors.<xref rid="r26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="r27" ref-type="bibr"><sup>27</sup></xref> Indoleamine 2,3-dioxygenase (IDO) which has immunosuppressive functions due to enzymatic activities catalyzing the essential amino acid L-tryptophan was also expressed on 32% of B-cell lymphoma cases and IDO expression was associated to poor outcome.<xref rid="r28" ref-type="bibr"><sup>28</sup></xref> These immunosuppressive molecules are also expressed on myeloid cells such as tumor associated macrophages.<xref rid="r29" ref-type="bibr"><sup>29</sup></xref> Down-regulation of these factors might be linked to SR in lymphoma cases.</p><p>In conclusion, the expression of CD80/CD86 on lymphoma cells is potentially associated with activation of anti-lymphoma T cell responses and clinical SR. HLA-DR expression on lymphoma cells may also influence activation of lymphoma-specific CD4-positive helper T cells in the microenvironment. As a therapeutic strategy, anti-CTLA-4 antibody rather than anti-PD-1/PD-L1 antibody may be helpful to enhance anti-lymphoma T cell response in cases of CD80/CD86-positive lymphoma.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICT OF INTEREST:</bold> All authors have no financial competing interests to declare.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghatalia</surname><given-names>P</given-names></name><name><surname>Morgan</surname><given-names>CJ</given-names></name><name><surname>Sonpavde</surname><given-names>G</given-names></name></person-group>
<article-title>Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials.</article-title>
<source>Crit Rev Oncol Hematol</source>. <year>2016</year>; <volume>98</volume>: <fpage>122</fpage>-<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2015.10.018</pub-id><pub-id pub-id-type="pmid">26597016</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokuhira</surname><given-names>M</given-names></name><name><surname>Tamaru</surname><given-names>J</given-names></name><name><surname>Kizaki</surname><given-names>M</given-names></name></person-group>
<article-title>Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.</article-title>
<source>J Clin Exp Hematop</source>. <year>2019</year>; <volume>59</volume>: <fpage>72</fpage>-<lpage>92</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.19007</pub-id><pub-id pub-id-type="pmid">31257348</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Yoshimoto</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment.</article-title>
<source>Front Immunol</source>. <year>2018</year>; <volume>9</volume>: <fpage>621</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00621</pub-id><pub-id pub-id-type="pmid">29670617</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Ishihara</surname><given-names>M</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy.</article-title>
<source>J Clin Exp Hematop</source>. <year>2019</year>; <volume>59</volume>: <fpage>17</fpage>-<lpage>21</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.18020</pub-id><pub-id pub-id-type="pmid">30918140</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>R</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name></person-group>
<article-title>Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus: a case report and review of the literature.</article-title>
<source>J Clin Exp Hematop</source>. <year>2007</year>; <volume>47</volume>: <fpage>23</fpage>-<lpage>26</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.47.23</pub-id><pub-id pub-id-type="pmid">17510535</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>T</given-names></name><name><surname>Ichimura</surname><given-names>K</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name></person-group>
<article-title>Spontaneous regression of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.</article-title>
<source>J Clin Exp Hematop</source>. <year>2007</year>; <volume>47</volume>: <fpage>79</fpage>-<lpage>81</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.47.79</pub-id><pub-id pub-id-type="pmid">18040147</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>Gong</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Spontaneous regression of mantle cell lymphoma: a report of four cases.</article-title>
<source>Cancer Commun</source>. <year>2018</year>; <volume>38</volume>: <fpage>30</fpage>. <pub-id pub-id-type="doi">10.1186/s40880-018-0306-z</pub-id><pub-id pub-id-type="pmid">29843782</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappauf</surname><given-names>H</given-names></name><name><surname>Gallmeier</surname><given-names>WM</given-names></name><name><surname>W&#x000fc;nsch</surname><given-names>PH</given-names></name><etal/></person-group>
<article-title>Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer.</article-title>
<source>Ann Oncol</source>. <year>1997</year>; <volume>8</volume>: <fpage>1031</fpage>-<lpage>1039</lpage>. <pub-id pub-id-type="doi">10.1023/A:1008209618128</pub-id><pub-id pub-id-type="pmid">9402178</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janiszewska</surname><given-names>AD</given-names></name><name><surname>Poletajew</surname><given-names>S</given-names></name><name><surname>Wasiuty&#x00144;ski</surname><given-names>A</given-names></name></person-group>
<article-title>Reviews Spontaneous regression of renal cell carcinoma.</article-title>
<source>Contemp Oncol (Pozn)</source>. <year>2013</year>; <volume>2</volume>: <fpage>123</fpage>-<lpage>127</lpage>. <pub-id pub-id-type="doi">10.5114/wo.2013.34613</pub-id><pub-id pub-id-type="pmid">23788977</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bramhall</surname><given-names>RJ</given-names></name><name><surname>Mahady</surname><given-names>K</given-names></name><name><surname>Peach</surname><given-names>AHS</given-names></name></person-group>
<article-title>Spontaneous regression of metastatic melanoma &#x02013; Clinical evidence of the abscopal effect.</article-title>
<source>European Journal of Surgical Oncology (EJSO)</source>. <year>2014</year>; <volume>40</volume>: <fpage>34</fpage>-<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2013.09.026</pub-id><pub-id pub-id-type="pmid">24139999</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horii</surname><given-names>R</given-names></name><name><surname>Akiyama</surname><given-names>F</given-names></name><name><surname>Kasumi</surname><given-names>F</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>G</given-names></name></person-group>
<article-title>Spontaneous &#x0201c;healing&#x0201d; of breast cancer.</article-title>
<source>Breast Cancer</source>. <year>2005</year>; <volume>12</volume>: <fpage>140</fpage>-<lpage>144</lpage>. <pub-id pub-id-type="doi">10.2325/jbcs.12.140</pub-id><pub-id pub-id-type="pmid">15858446</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasquez</surname><given-names>M</given-names></name><name><surname>Tenesaca</surname><given-names>S</given-names></name><name><surname>Berraondo</surname><given-names>P</given-names></name></person-group>
<article-title>New trends in antitumor vaccines in melanoma.</article-title>
<source>Ann Transl Med</source>. <year>2017</year>; <volume>5</volume>: <fpage>384</fpage>. <pub-id pub-id-type="doi">10.21037/atm.2017.09.09</pub-id><pub-id pub-id-type="pmid">29114542</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turajlic</surname><given-names>S</given-names></name><name><surname>Litchfield</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.</article-title>
<source>Lancet Oncol</source>. <year>2017</year>; <volume>18</volume>: <fpage>1009</fpage>-<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30516-8</pub-id><pub-id pub-id-type="pmid">28694034</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Polak</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes.</article-title>
<source>Nature</source>. <year>2013</year>; <volume>499</volume>: <fpage>214</fpage>-<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmid">23770567</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dakappagari</surname><given-names>N</given-names></name><name><surname>Ho</surname><given-names>SN</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><etal/></person-group>
<article-title>CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.</article-title>
<source>Cytometry B Clin Cytom</source>. <year>2012</year>; <volume>82B</volume>: <fpage>112</fpage>-<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.b.20631</pub-id><pub-id pub-id-type="pmid">22076940</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimsza</surname><given-names>LM</given-names></name><name><surname>Roberts</surname><given-names>RA</given-names></name><name><surname>Miller</surname><given-names>TP</given-names></name><etal/></person-group>
<article-title>Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.</article-title>
<source>Blood</source>. <year>2004</year>; <volume>103</volume>: <fpage>4251</fpage>-<lpage>4258</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2003-07-2365</pub-id><pub-id pub-id-type="pmid">14976040</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Townsend</surname><given-names>SE</given-names></name><name><surname>Su</surname><given-names>FW</given-names></name><name><surname>Atherton</surname><given-names>JM</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group>
<article-title>Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.</article-title>
<source>Cancer Res</source>. <year>1994</year>; <volume>54</volume>: <fpage>6477</fpage>-<lpage>6483</lpage>.<pub-id pub-id-type="pmid">7527298</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>X</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group>
<article-title>The B7 family and cancer therapy: costimulation and coinhibition.</article-title>
<source>Clin Cancer Res</source>. <year>2007</year>; <volume>13</volume>: <fpage>5271</fpage>-<lpage>5279</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1030</pub-id><pub-id pub-id-type="pmid">17875755</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Seigne</surname><given-names>J</given-names></name><name><surname>Diaz</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.</article-title>
<source>J Urol</source>. <year>2002</year>; <volume>167</volume>: <fpage>1995</fpage>-<lpage>2000</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5347(05)65071-9</pub-id><pub-id pub-id-type="pmid">11956426</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Hardwick</surname><given-names>NR</given-names></name><name><surname>Guinn</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia.</article-title>
<source>Cancer Immunol Immunother</source>. <year>2006</year>; <volume>55</volume>: <fpage>1017</fpage>-<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-006-0129-7</pub-id><pub-id pub-id-type="pmid">16450142</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raez</surname><given-names>LE</given-names></name><name><surname>Cassileth</surname><given-names>PA</given-names></name><name><surname>Schlesselman</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.</article-title>
<source>J Clin Oncol</source>. <year>2004</year>; <volume>22</volume>: <fpage>2800</fpage>-<lpage>2807</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2004.10.197</pub-id><pub-id pub-id-type="pmid">15254047</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Gion</surname><given-names>Y</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name></person-group>
<article-title>A review of EBV-positive mucocutaneous ulcers focusing on clinical and pathological aspects.</article-title>
<source>J Clin Exp Hematop</source>. <year>2019</year>; <volume>59</volume>: <fpage>64</fpage>-<lpage>71</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.18039</pub-id><pub-id pub-id-type="pmid">31257347</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Airoldi</surname><given-names>I</given-names></name><name><surname>Guglielmino</surname><given-names>R</given-names></name><name><surname>Carra</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes.</article-title>
<source>Haematologica</source>. <year>2002</year>; <volume>87</volume>: <fpage>434</fpage>-<lpage>442</lpage>.<pub-id pub-id-type="pmid">11940489</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Temizoz</surname><given-names>B</given-names></name><name><surname>Kuroda</surname><given-names>E</given-names></name><name><surname>Ishii</surname><given-names>KJ</given-names></name></person-group>
<article-title>Vaccine adjuvants as potential cancer immunotherapeutics.</article-title>
<source>Int Immunol</source>. <year>2016</year>; <volume>28</volume>: <fpage>329</fpage>-<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxw015</pub-id><pub-id pub-id-type="pmid">27006304</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyasu</surname><given-names>J</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.</article-title>
<source>Blood</source>. <year>2015</year>; <volume>126</volume>: <fpage>2193</fpage>-<lpage>2201</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2015-02-629600</pub-id><pub-id pub-id-type="pmid">26239088</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>B-cell receptor&#x02013;mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.</article-title>
<source>Blood</source>. <year>2018</year>; <volume>132</volume>: <fpage>1805</fpage>-<lpage>1817</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2018-03-841015</pub-id><pub-id pub-id-type="pmid">30209121</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Horlad</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines.</article-title>
<source>J Clin Exp Hematop</source>. <year>2017</year>; <volume>57</volume>: <fpage>21</fpage>-<lpage>25</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.17006</pub-id><pub-id pub-id-type="pmid">28496056</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ninomiya</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Tsurumi</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.</article-title>
<source>Ann Hematol</source>. <year>2011</year>; <volume>90</volume>: <fpage>409</fpage>-<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1007/s00277-010-1093-z</pub-id><pub-id pub-id-type="pmid">20938662</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyasato</surname><given-names>Y</given-names></name><name><surname>Takashima</surname><given-names>Y</given-names></name><name><surname>Takeya</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.</article-title>
<source>J Clin Exp Hematop</source>. <year>2018</year>; <volume>58</volume>: <fpage>95</fpage>-<lpage>101</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.18001</pub-id><pub-id pub-id-type="pmid">29998979</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>K</given-names></name><name><surname>Kosaki</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples.</article-title>
<source>J Clin Exp Hematop</source>. <year>2017</year>; <volume>57</volume>: <fpage>31</fpage>-<lpage>36</lpage>. <pub-id pub-id-type="doi">10.3960/jslrt.17017</pub-id><pub-id pub-id-type="pmid">28679964</pub-id></mixed-citation></ref></ref-list></back></article>